1. Media & Marketing

Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes

Written by Posted on Less than 0 min read

Our news-laden summer is ending. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline:

P.S. Join my nearly 65,000 LinkedIn followers for daily links to neat stuff, along with sharp and thoughtful commentary from the DCI community.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 40
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Media & Marketing

Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting

Eeek! It’s time for the Drug Channels Halloween roundup of terrifying tales from the dark corners of the healthcare system. Gather your favorite demon hunters and help maintain the Honmoon. This month’s tricks and treats include: Vampiric! How vertically integrated insurers can drain the lifeblood from the U.S. healthcare system Boo! Chilling stories of the shady […]
2 min read
0
  1. Data & Insights

New Study Reveals Five Crucial Priorities Shaping The Future of Patient Services

Today’s guest post comes from Scott Genone, Chief Product Officer at CareMetx. Scott shares key takaways from CareMetx’s recent survey of over 100 industry leaders. He outlines four trends that will define the future of patient services. To view the full survey results, download The 2025 Patient Services Report: Provider Engagement is Make or Break for […]
2 min read
0
  1. Trends & External Forces

U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges

It’s time for Drug Channels’ annual examination of U.S. brand-name drug pricing. For 2025, brand-name drugs’ average list prices grew by only 3.5%, but net prices declined. When manufacturers’ rebates and discounts are factored in, drugs’ average net prices—both before and after inflation—fell. Details and additional commentary below. As I have been predicting, the gross-to-net […]
2 min read
0
  1. Data & Insights

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access

It’s time for Drug Channels’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. This year’s review includes the following nine companies: Bristol Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, Johnson & Johnson, Sanofi, Takeda, Teva, and UCB. You can find links to each company’s data below. These data highlight divergent trends […]
3 min read
0
  1. Data & Insights

Vertical Integration Redux: How Pharmaceutical Wholesalers Are Transforming the Buy-and-Bill Market (Video)

ICYMI, the largest three pharmaceutical wholesalers—Cardinal Health, Cencora, and McKesson—are using vertical integration to build significant market positions in businesses beyond drug distribution. In the video clip below, I review the vertical integration status of the largest three pharmaceutical wholesalers, illustrated in the chart below. [Click to Enlarge] I also: Explain how wholesalers have strengthened […]
2 min read
0
  1. Data & Insights

When Payers Become Producers: Inside the PBM Private-Labeling Trend

Today’s guest post comes from Benjamin Hinton II, Senior Market Access Solutions Analyst at MMIT. Benjamin reviews the growing trend of PBMs vertically integrating into the production of biosimilars. He shares data from an MMIT survey of 20 large national payers, independent plans, Blues affiliates and PBMs (excluding participants). The findings shed light on payers’ […]
2 min read
0
  1. Data & Insights

Markup Madness 2025: Hospitals, Insurers, and the Broken Buy-and-Bill Market for Biosimilars

After multiple years of mandated disclosure of negotiated hospital-insurer rates, those of us who follow the buy-and-bill channel might have expected transparency to reduce drug price variability, lower hospital markups, and accelerate adoption of lower-cost biosimilars. Alas, that’s not what the latest data reveal. DCI’s analysis of four national commercial insurers—Aetna, Anthem, Cigna, and UnitedHealthcare—and […]
2 min read
0
  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channels Outlook 2026 . Click here to see the original post from September 2025. Over the summer, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the latest projections for U.S. spending on healthcare. (See links […]
2 min read
0
  1. Department: HBC

Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble

On Monday, Cigna announced that it would be abandoning traditional manufacturer rebates and moving to a new, “rebate-free” approach—essentially a point-of-sale (POS) rebate model paired with a cost-plus pharmacy reimbursement framework. Here’s the press release. Moving manufacturers’ rebates and discounts to the point of dispensing is a big win for patients, who can share in […]
2 min read
0
  1. Data & Insights

No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows

Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx. Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated […]
2 min read
0
  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts

Over the summer, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the latest projections for U.S. spending on healthcare. (See links below.) These data provide the latest official and apolitical look at the future of U.S. healthcare spending. The top line projections highlight the government’s official view that prescription drugs dispensed […]
2 min read
0
  1. Trends & External Forces

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs

For 2026, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)—have once again excluded hundreds of drugs from their standard formularies. Our updated counts appear below. The 2026 lists highlight how formulary preferences for Humira and Stelara are dominated by private-label biosimilars affiliated with the same […]
2 min read
0
  1. Data & Insights

Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different

Today’s guest post is from Dr. Richard Faris, Chief Commercial and Clinical Officer at PANTHERx Rare. Richard examines key considerations in launching rare disease therapies. He  argues that targeted reach, tighter relationships, and data-driven collaboration can improve success for both patients and manufacturers. To learn more, download PANTHERx Rare’s free guide: From PDUFA to Patient: A […]
2 min read
0
  1. Trends & External Forces

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers’ preparation. To learn more, register […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026

Happy New Year, everyone! As always, thank you for welcoming Drug Channels into your inboxes, browsers, and apps. I’m continually inspired by the diverse and thoughtful people who follow, share, and challenge our work. Our DCI community now includes more than 110,000 subscribers and followers across the industry. If you haven’t already done so, you […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s Copay, Reimbursement and Access Congress 2025

Informa Connect’s Copay, Reimbursement and Access Congress 2025 November 18-20, 2025 | Hilton New Brunswick, East Brunswick, NJ Exclusive Offer–Use promo USAVE25 to save 10%* on your registration The healthcare landscape continues to evolve at an unprecedented pace, bringing new challenges and opportunities for patient access and affordability. As legislation shifts, market forces disrupt and […]
3 min read
0
  1. Sponsored

IRA Reality Check: Four Strategies for Adapting Hub and Copay Programs

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris reviews recent developments for the Inflation Reduction Act of 2022 (IRA). He then recommends four IRA-related adjustments that manufacturers should make to their patient support programs. To learn more, register for ConnectiveRx’s free webinar on September 17: IRA Reality Check: Adapting […]
2 min read
0
  1. Trends & External Forces

Drug Channels Outlook 2025 (NEW Live Video Webinar)

Adam J. Fein, Ph.D., president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2025 This event will be broadcast live on Friday, December 13, 2024, from 12:00 p.m. to 1:30 p.m. ET This post describes the event and […]
3 min read
0
  1. Owned Brands (Private Label)

The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market

The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dynamics. But unlike the chaotic rollout of Humira biosimilars, pharmacy benefit managers (PBMs) came prepared. Private label strategies, aggressive pricing, and exclusive formulary deals have transformed what might have been a slow-crawling biosimilar introduction into a full-on […]
2 min read
0
  1. Data & Insights

The Promise of a Direct-to-Patient Model—Breaking Down What’s Really Needed for Better Patient Access

Today’s guest post comes from Greg Skalicky, President, EVERSANA and Faruk Abdullah, President, Professional Services & Chief Business Officer, EVERSANA Greg and Faruk walk through the marketplace pressures driving Direct-to-Patient commercialization models. They argue that a technology-enabled infrastructure,  combined with clinical and reimbursement support specialists, can improve  patients’ access to new therapies, shorten the time […]
2 min read
0
Next